Clinical trials: Carcinoma of Prostate (Disorder)
Prostate Cancer, Molecular Imaging
Molecular Profiling of MRI-PSMA PET Discordance in Prostate Cancer
MRI and PSMA-PET are highly sensitive imaging tools for prostate cancer, yet they often detect different lesions. These discordant findings pose clinical uncertainty because their biological significance is unclear.
- Conditions
- Prostate Cancer, Molecular Imaging, Transcriptomics, RNA
- Trial name
- MP-PET-MRI (NCT07485257)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Prostate Cancer
Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer
High risk prostate cancer (PCa) had worse outcomes on radical treatment results, short-time oncological results, even cancer-specific survival, than those low or mediate risk PCa.
- Trial name
- NCT04356430
- Testing
- Abiraterone Acetate, Prednisone, Goserelin 10.8 mg
- Where
- China
- Volunteers
- 75 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
The BIOPRES Trial: Transrectal BIOpsies of the PRostate: End Versus Side-firing
The purpose of this study is to study the difference in prostate cancer between two prostate biopsy techniques, namely end-firing and side-firing. These differ in the angle at which the prostate is biopsied.
- Trial name
- BIOPRES (NCT00851292)
- Testing
- TRUS probe
- Where
- Netherlands
- Volunteers
- 800 people
- Sponsor
- Amphia Hospital
Prostate Cancer
Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
18F-labeled prostate-specific membrane antigen (PSMA) ligand-positron emission tomography (PET) offers advantages over 68Ga-labeled PSMA ligands. Al18F-PSMA-617 is a novel 18F-PSMA compound used for prostate cancer (PCa) imaging.
- Trial name
- NCT05841992
- Testing
- Al18F-PSMA-617, 68Ga-PSMA-617
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer, Castration Sensitive Prostate Cancer
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery
The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PET PSMA-response adapted SABR for poly-metastatic castration sensitive…
- Conditions
- Prostate Cancer, Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer, Adaptive Radiotherapy
- Trial name
- RIPCORD (NCT07674771)
- Testing
- Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
The active ingredient of Pamorelin® 11,25 mg is Triptorelin. Triptorelin is a substitute for a natural hormone produced in the body called Gonadotrophin-releasing hormone (GnRH).
- Trial name
- NCT00444639
- Testing
- Triptorelin (Decapeptyl®)
- Where
- 15 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Ipsen
Prostatic Neoplasms
Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer
Biochemical recurrence develops in approximately 30-40% of men with locally advanced prostate cancer who undergo radical prostatectomy.
- Trial name
- NCT01759836
- Testing
- Atorvastatin 20mg
- Where
- South Korea
- Volunteers
- 364 people
- Sponsor
- Asan Medical Center
Prostatic Neoplasms
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate pharmacokinetics (PK) following a single dose and multiple dose treatment and the safety of apalutamide in Chinese participants with metastatic castration resistant prostate cancer (mCRPC)…
- Trial name
- NCT03523442
- Testing
- Apalutamide
- Where
- 4 sites in China
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC
Advanced or Metastatic Solid Tumors
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer.
- Trial name
- NCT04586270
- Testing
- TAS0612
- Where
- 4 sites in United States, France
- Volunteers
- 47 people
- Sponsor
- Taiho Oncology, Inc.
Colon Cancer, Gastric Cancer
Integrated Care Pathway in Oncology (PASSION)
A centralized unit for integrated management of care pathway in Oncology has been created. This unit settles the patients' appointments (biopsy, intravenous device, chemotherapy, imaging, oncologist...).
- Conditions
- Colon Cancer, Gastric Cancer, Pancreatic Cancer, Thoracic Neoplasms
- Trial name
- PASSION (NCT04235556)
- Testing
- Care pathway unit
- Where
- France
- Volunteers
- 1,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostatic Neoplasms
Prostate Cancer Biobank
Carcinoma of the prostate is the second most commonly diagnosed cancer and occurs predominantly in older men - almost two-thirds of those affected are over 65 years of age.
- Trial name
- NCT04024475
- Testing
- Observation
- Where
- 12 sites in Switzerland
- Volunteers
- 1,323 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer
PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer
In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy.
- Trial name
- NCT07291557
- Testing
- Prostate Only Radiation Therapy (PORT), Prostate + Whole Pelvis Radiation Therapy (P-WPRT)
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- AHS Cancer Control Alberta
Prostatic Cancer
Salvage HIFU for Local Recurrence in the Prostatic Bed After Prostatectomy and External Beam Radiation Therapy : Preliminary Results
Retrospective monocentric analysis performed on patients treated with salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT.
- Trial name
- Salvage HIFU (NCT04421781)
- Testing
- Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Prostate Volume Changes Following Prostate Brachytherapy With Iodine-125 Seeds
The size of the prostate changes due to insertion of the radioactive seeds. We will measure the prostate size, before and after the procedure.
- Trial name
- NCT00348465
- Testing
- Brachytherapy with Iodine-125 seeds
- Volunteers
- 29 people
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Prostate Cancer
Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
This clinical study will evaluate the role of combination therapy of Provenge followed by docetaxel for patients with metastatic castration-resistant prostate cancer (CRPC, (prostate cancer that is resistant to medical or…
- Trial name
- NCT02793219
- Testing
- Sipuleucel-T, Docetaxel
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Breast Carcinoma, Colon Carcinoma
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
This clinical quality improvement study reviews and develops a clinical operations workflow to identify cancer patients who meet criteria for genetic counseling and testing.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma
- Trial name
- NCT04902144
- Testing
- Electronic Health Record Review, Questionnaire Administration, Behavioral Intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
The WINGMEN trial aims to understand how a hormone-like protein called insulin-like growth factor (IGF) helps prostate cancers grow and become aggressive.
- Trial name
- WINGMEN (NCT05110495)
- Testing
- Xentuzumab
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Oxford
Prostate Cancer Metastatic Disease, Prostate Cancers
Using FAPI PET/MRI to Evaluate Prostate Cancer
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue.
- Trial name
- NCT06675357
- Testing
- FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer, Hypoxia
Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
Due to the rapid growth, tumour demand for oxygen is often higher than what can be delivered by the newly forming blood vessels.
- Trial name
- HYPROGEN (NCT05702619)
- Testing
- Optional non-IMP pimonidazole, CT-guided Bone Biopsy, TRUS-guided Targeted Transperineal Prostate Biopsy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- The Christie NHS Foundation Trust
PROSTATE CANCER
Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Prostate Cancer
The goal of this clinical trial is to compare two dose schedules of stereotactic radiation therapy in patients with localized prostate cancer.
- Trial name
- SABR-Dual (NCT06027892)
- Testing
- Two-fraction stereotactic radiotherapy, Five-fraction stereotactic radiotherapy
- Where
- Israel
- Volunteers
- 562 people
- Sponsor
- Rabin Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.